Aytu Biopharma (AYTU) Receivables - Net (2015 - 2026)

Aytu Biopharma (AYTU) has 12 years of Receivables - Net data on file, last reported at $24.5 million in Q1 2026.

• On a quarterly basis, Receivables - Net fell 31.64% year-over-year to $24.5 million in Q1 2026; TTM through Mar 2026 was $24.5 million, a 31.64% decrease from a year earlier, with the FY2025 full-year figure at $32.3 million, up 27.6% from the prior year.
• Receivables - Net for Q1 2026 stood at $24.5 million, down from $30.9 million in the prior quarter.
• Over the last five years, Receivables - Net for AYTU reached as high as $35.8 million in Q1 2025 and fell as low as $23.2 million in Q3 2024.
• Historically, Receivables - Net has averaged $28.8 million across 5 years, with a median of $29.4 million in 2023.
• Across the five-year window, Receivables - Net surged 43.46% in 2025 and sank 31.64% in 2026, its largest moves.
• Year by year, Receivables - Net stood at $25.5 million in 2022, then gained by 15.29% to $29.4 million in 2023, then slipped by 13.6% to $25.4 million in 2024, then increased by 21.73% to $30.9 million in 2025, then declined by 20.81% to $24.5 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $24.5 million in Q1 2026, $30.9 million in Q4 2025, and $33.2 million in Q3 2025.